WO1994024163A3 - Bispecific antigen-binding molecules - Google Patents

Bispecific antigen-binding molecules Download PDF

Info

Publication number
WO1994024163A3
WO1994024163A3 PCT/US1994/003171 US9403171W WO9424163A3 WO 1994024163 A3 WO1994024163 A3 WO 1994024163A3 US 9403171 W US9403171 W US 9403171W WO 9424163 A3 WO9424163 A3 WO 9424163A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antigens
fork
antigen fork
cells
Prior art date
Application number
PCT/US1994/003171
Other languages
French (fr)
Other versions
WO1994024163A2 (en
Inventor
David B Ring
Sylvia T Hsieh-Ma
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Priority to EP94921881A priority Critical patent/EP0804487A2/en
Priority to AU72410/94A priority patent/AU7241094A/en
Priority to JP6523202A priority patent/JPH08510116A/en
Publication of WO1994024163A2 publication Critical patent/WO1994024163A2/en
Publication of WO1994024163A3 publication Critical patent/WO1994024163A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

The present invention relates to a class of molecules called 'antigen forks' that inhibit cell growth. These antigen forks possess separate binding elements for two different cell surface antigens and are believed to heterologously crosslink the antigens by binding to them. The two antigens recognized by an antigen fork differ in at least one cellular functional quality, but are simultaneously expressed on the surface of at least one cell type targeted for killing or growth inhibition. Such targeted cells include tumor cells and virally-infected cells. It is preferred that the antigen fork be designed so that the two antigens it recognizes are seldom or never simultaneously expressed on normal cells. The antigen fork is preferably a bispecific antibody, but may also be constructed from binding elements that are not derived from antibodies. The present invention also relates to a hybrid hybridoma that produces an antigen fork and a method for treating a patient with cancer or a viral infection by administering an antigen fork. It is preferred that a cytotoxic agent such as deferoxamine or cisplatin is sequentially or simultaneously administered to the patient.
PCT/US1994/003171 1993-04-09 1994-03-21 Bispecific antigen-binding molecules WO1994024163A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94921881A EP0804487A2 (en) 1993-04-09 1994-03-21 Bispecific antigen-binding molecules
AU72410/94A AU7241094A (en) 1993-04-09 1994-03-21 Bispecific antigen-binding molecules
JP6523202A JPH08510116A (en) 1993-04-09 1994-03-21 Bispecific antigen binding molecule

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4596993A 1993-04-09 1993-04-09
US16398893A 1993-12-07 1993-12-07
US08/163,988 1993-12-07
US08/045,969 1993-12-07

Publications (2)

Publication Number Publication Date
WO1994024163A2 WO1994024163A2 (en) 1994-10-27
WO1994024163A3 true WO1994024163A3 (en) 1994-12-08

Family

ID=26723417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003171 WO1994024163A2 (en) 1993-04-09 1994-03-21 Bispecific antigen-binding molecules

Country Status (5)

Country Link
EP (1) EP0804487A2 (en)
JP (1) JPH08510116A (en)
AU (1) AU7241094A (en)
CA (1) CA2160224A1 (en)
WO (1) WO1994024163A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531348A1 (en) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antibodies with two or more specificities for the selective elimination of cells in vivo
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2011115062A1 (en) * 2010-03-15 2011-09-22 国立大学法人 岡山大学 Adjuvant having anti-tumor effect
CN106029682B (en) 2013-12-27 2021-04-13 中外制药株式会社 Method for purifying antibody having low isoelectric point
TW202216788A (en) * 2020-06-26 2022-05-01 日商協和麒麟股份有限公司 Bispecific antibody binding to GPC3 and TfR

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256714A2 (en) * 1986-08-01 1988-02-24 Cetus Oncology Corporation Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
EP0468637A1 (en) * 1990-06-22 1992-01-29 Eli Lilly And Company In vivo targeting with bifunctional antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256714A2 (en) * 1986-08-01 1988-02-24 Cetus Oncology Corporation Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
EP0468637A1 (en) * 1990-06-22 1992-01-29 Eli Lilly And Company In vivo targeting with bifunctional antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
T. SHI ET AL.: "Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 141, no. 2, 9 August 1991 (1991-08-09), AMSTERDAM, THE NETHERLANDS, pages 165 - 175 *
Y. YU ET AL.: "Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells.", CANCER RESEARCH, vol. 50, no. 11, 1 June 1990 (1990-06-01), PHILADELPHIA PA, USA, pages 3231 - 3238 *

Also Published As

Publication number Publication date
AU7241094A (en) 1994-11-08
WO1994024163A2 (en) 1994-10-27
CA2160224A1 (en) 1994-10-27
EP0804487A2 (en) 1997-11-05
JPH08510116A (en) 1996-10-29

Similar Documents

Publication Publication Date Title
US5643759A (en) Method for preparing bispecific monoclonal antibodies
WO2002020039A3 (en) Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
US20150105541A1 (en) Antibody-active agent conjugates and methods of use
AU2005215874B2 (en) Anti-EpCAM immunoglobulins
WO2004006847A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
CA2579523A1 (en) Atad3a-binding molecules for treatment, detection and prevention of cancer
GB9009548D0 (en) Chimeric antibody and method
EP1245676A4 (en) Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
WO2004065547A3 (en) Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
WO2002043661A3 (en) Recombinant anti-cd30 antibodies and uses thereof
WO2001064751A3 (en) High potency recombinant antibodies and method for producing them
NZ568403A (en) CD20-specific antibodies and methods of employing same
DK0751781T3 (en) Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic diseases
WO2005044307A3 (en) Methods of therapy for b cell-related cancers
Zone et al. IgA autoimmune disorders: development of a passive transfer mouse model
CA2227548A1 (en) Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
EP0350690A3 (en) Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom
US5830473A (en) Antibodies against T cells as therapeutics
SI1684770T1 (en) Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer
WO1994024163A3 (en) Bispecific antigen-binding molecules
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR CA CN CZ FI GE HU JP KG KR LV MD NO NZ PL RO RU SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994921881

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2160224

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994921881

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994921881

Country of ref document: EP